Ayaka Tanifuji, Satoko Ohfuji, Kosuke Matsumoto, Masanori Abe, Atsumasa Komori, Atsushi Takahashi, Kazuhito Kawata, Ken Sato, Satoru Joshita, Takeji Umemura, Masayuki Ueno, Nobuaki Nakayama, Keisuke Kakisaka, Teruko Arinaga-Hino, Koichi Ito, Sachiko Kanai, Ryo Miura, Toshihiko Arizumi, Yoshinari Asaoka, Takanori Ito, Tetsuya Shimizu, Hiroshi Yoshida, Masayuki Ohta, Suguru Mizuno, Hiroyuki Isayama, Youichi Morimoto, Satoshi Mochida, Hiromasa Ohira, Atsushi Tanaka
AIM: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire-based, cross-sectional study to determine the safety and effectiveness of the SARS-CoV-2 vaccines in Japanese patients with intractable hepatobiliary disease. METHODS: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study...
February 1, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology